Threshold Pharmaceuticals Announces New Phase 1/2 Data On TH-302 In Multiple Myeloma to Be Presented At The 2014 ASH Annual Meeting

Threshold Pharmaceuticals, Inc.

today announced that new data from an ongoing Phase 1/2 trial evaluating TH-302 and low-dose dexamethasone with or without the proteasome inhibitor bortezomib (Velcade(R)) in patients with relapsed/refractory multiple myeloma will be presented in a poster at the 56th Annual Meeting of the American Society of Hematology (ASH) held in San Francisco, California, from December 6 - 9, 2014 (Abstract #2142). The poster titled, "Phase 1/2 Trial of TH-302 and Dexamethasone without or with Bortezomib (TBorD) in Patients with Relapsed/Refractory Multiple Myeloma" (Abstract #2142) will be presented during Session 653 titled, "Myeloma: Therapy, e xcluding Transplantation: Poster I" on Saturday, December 6, 2014 from 5:30 PM - 7:30 PM at the Moscone Center, West Building, Level 1.